■医疗保健对于控制哮喘至关重要,然而,家庭支持的医疗保健是否能改善儿童哮喘的治疗效果尚不清楚.
■将入选患者随机分为对照组和干预组。通过1s内用力呼气量作为用力肺活量(FEV1/FVC)和呼出气一氧化氮(FeNO)的百分比来评估肺功能。通过儿童哮喘控制测试和小儿哮喘生活质量问卷评估哮喘控制和生活质量。通过酶联免疫吸附试验测定炎性细胞因子白细胞介素-6(IL-6)和白细胞介素-17(IL-17)。
■两组哮喘患儿及其家长的基本特征无显著差异。干预组FEV1/FVC的增加高于对照组(76.47±10.76%vs69.76±8.88%,干预后p=0.001),干预组FeNO下降幅度更大(30.43±6.85bbpvs35.64±6.62bbp,干预后p=0.003)。家庭支持的医疗保健大大改善了儿童哮喘治疗后的哮喘控制和生活质量。同时,炎性细胞因子IL-17(干预组118.14±25.79pg/mL,对照组142.86±28.68pg/mL,干预后p=0.004)和IL-6(干预组103.76±23.11pg/mL,对照组119.73±22.68pg/mL,干预后p=0.009)通过家庭支持的医疗保健干预显着降低。重要的是,急性加重(干预组80.8%,对照组95.7%,p=0.030)和再住院病例(干预组为88.5%,对照组为100%,p=0.028)也因家庭支持的医疗干预而下降。
■家庭支持的医疗保健可改善肺功能和生活质量,同时减轻炎症,急性加重,儿童哮喘常规治疗后再住院。
UNASSIGNED: Healthcare is essential for asthma control, however, whether family-supported healthcare improves therapeutic effects in childhood asthma remains unclear.
UNASSIGNED: The enrolled patients were randomly divided into control and intervention groups. The pulmonary function was evaluated by forced expiratory volume in 1 s as a percentage of forced vital capacity (FEV1/FVC) and fractional exhaled nitric oxide (FeNO). Asthma control and life quality were assessed via a childhood asthma control test and pediatric asthma quality of life questionnaire. Inflammatory cytokines interleukin-6 (IL-6) and interleukin-17 (IL-17) were determined by enzyme-linked immunosorbent assay.
UNASSIGNED: No significant differences existed in the basic characteristics of asthma children and their parents among two groups. The increase of FEV1/FVC was higher in the intervention group versus the control group (76.47 ± 10.76% vs 69.76 ± 8.88%, p = 0.001 at the time of post-intervention), and the decrease of FeNO was greater in the intervention group (30.43 ± 6.85 bbp vs 35.64 ± 6.62 bbp, p = 0.003 at the time of post-intervention). Family-supported healthcare highly improved asthma control and quality of life in childhood asthma post-treatment. Meanwhile, the inflammatory cytokines IL-17 (118.14 ± 25.79 pg/mL in intervention group vs 142.86 ± 28.68 pg/mL in control group, p = 0.004 at the time of post-intervention) and IL-6 (103.76 ± 23.11 pg/mL in intervention group vs 119.73 ± 22.68 pg/mL in control group, p = 0.009 at the time of post-intervention) significantly decreased by family-supported healthcare intervention. Importantly, acute exacerbation (80.8% in intervention group vs 95.7% in control group, p = 0.030) and rehospitalization cases (88.5% in intervention group vs 100% in control group, p = 0.028) also decreased by family-supported healthcare intervention.
UNASSIGNED: Family-supported healthcare improves pulmonary function and quality of life while alleviates inflammation, acute exacerbation, and rehospitalization in childhood asthma post-routine treatment.